(Alliance News) - Sensyne Health PLC announced on Friday it had signed a five-year strategic research agreement with Cambridge University Hospital NHS Foundation Trust that will enable the application of clinical AI research.
The agreement will use clinical AI research to analyse de-identified patient records in the hope of providing new understanding and treatments for various diseases.
The partnership will cover research across the trust's areas of disease expertise and specialism in cancer, cardiovascular disease, and rare diseases.
The NHS trust will receive 4.3 million shares in Sensyne, representing 2.6% of the existing issued share capital of Sensyne. This brings the total share ownership held by NHS Trusts in Sensyne to 16%.
Cambridge University Hospital will also receive an investment of up to GBP350,000 a year from Sensyne over the five-year term of the contract for specific ongoing investments in information technology to enable the ethical curation and analysis of de-identified data under the strategic research agreement.
Chief Executive Officer Paul Drayson said: "Sensyne is delighted to be working with Cambridge University Hospitals NHS Foundation Trust, a leading national centre for the treatment of rare or complex conditions and a university teaching hospital with a worldwide reputation. Cambridge University Hospitals is also recognised as a leader in the use of digital tools and health data to improve patient care and has built a large, high quality data set as a result. The trust has invested heavily in its digital infrastructure and the curation of its data which means we can start work immediately. Together we aim to use the power of ethical AI to make a real difference in finding new and better ways to treat cancer and other complex diseases."
Shares in Sensyne Health closed flat at 90.00 pence on Friday in London.
By Heather Rydings; heatherrydings@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
